Firms
Samsara BioCapital
- Founded
- —
- Type
- Venture capital
Funds0
No funds on record yet.
Team
No team members on record yet.
Co-investing
Lightspeed
Alpha-9$175M · 2024-10-23Alpha-9 Oncology, Inc.$175M · 2024-10-23
Alpha-9 Oncology, Inc.$175M · 2024
ImmunOs$74M · 2022-06-08
ImmunOS$74M · 2022-06-08Abata Therapeutics$95M · 2021
Enlaza Therapeutics$100M · Unknown date
ARCH Venture Partners
DewPoint Therapeutics, Inc.$150M · 2022-02-03
Prime Medicine, Inc.$200M · 2021-07-13
Autobahn Therapeutics$76M · 2020-06-09
Prime Medicine, Inc.$— · Unknown date
Frazier Life Sciences
Alpha-9$175M · 2024-10-23Alpha-9 Oncology, Inc.$175M · 2024-10-23
Enlaza Therapeutics$100M · 2024-04-30Alpha-9 Oncology, Inc.$175M · 2024
General Catalyst
Alpha-9$175M · 2024-10-23Alpha-9 Oncology, Inc.$175M · 2024-10-23
Alpha-9 Oncology, Inc.$175M · 2024
DewPoint Therapeutics, Inc.$150M · 2022-02-03
Alexandria Venture Investments
Enlaza Therapeutics$100M · 2024-04-30
Autobahn Therapeutics$76M · 2020-06-09
Enlaza Therapeutics$100M · Unknown date
Cormorant Asset Management
ImmunOs$74M · 2022-06-08
Prime Medicine, Inc.$200M · 2021-07-13
Abcuro$200M · Unknown date
Delos Capital
Alpha-9$175M · 2024-10-23Alpha-9 Oncology, Inc.$175M · 2024-10-23
Alpha-9 Oncology, Inc.$175M · 2024
Longitude Capital
Alpha-9$175M · 2024-10-23Alpha-9 Oncology, Inc.$175M · 2024-10-23
Alpha-9 Oncology, Inc.$175M · 2024
Nextech Invest
Alpha-9$175M · 2024-10-23Alpha-9 Oncology, Inc.$175M · 2024-10-23
Alpha-9 Oncology, Inc.$175M · 2024
Amgen Ventures
Enlaza Therapeutics$100M · 2024-04-30
Enlaza Therapeutics$100M · Unknown date
F-Prime Capital
Prime Medicine, Inc.$200M · 2021-07-13
Prime Medicine, Inc.$— · Unknown date
GV
Prime Medicine, Inc.$200M · 2021-07-13
Prime Medicine, Inc.$— · Unknown date
Newpath Partners
Prime Medicine, Inc.$200M · 2021-07-13
Prime Medicine, Inc.$— · Unknown date
Pappas Capital
Enlaza Therapeutics$100M · 2024-04-30
Enlaza Therapeutics$100M · Unknown date
3E Bioventures Capital
DewPoint Therapeutics, Inc.$150M · 2022-02-03
Avalon Capital Group
Enlaza Therapeutics$100M · Unknown date
Avalon Ventures
Enlaza Therapeutics$100M · 2024-04-30
Bain Capital
Abcuro$200M · Unknown date
Bregua Corporation
Enlaza Therapeutics$100M · 2024-04-30
Bristol Myers Squibb
Autobahn Therapeutics$76M · 2020-06-09
BVF Partners L.P.
Autobahn Therapeutics$76M · 2020-06-09
Casdin Capital
Prime Medicine, Inc.$200M · 2021-07-13
Cowen Healthcare Investments
Autobahn Therapeutics$76M · 2020-06-09
J.P. Morgan Private Capital Life Sciences
Enlaza Therapeutics$100M · 2024-04-30
Jeito Capital
Eyebiotech Limited$65M · 2022-02-22
Leaps by Bayer
DewPoint Therapeutics, Inc.$150M · 2022-02-03
Lightspeed Venture Partners
Enlaza Therapeutics$100M · 2024-04-30
Mass General Brigham Ventures
Abcuro$200M · Unknown date
Maverick Ventures
DewPoint Therapeutics, Inc.$150M · 2022-02-03
Mirae Asset Capital
DewPoint Therapeutics, Inc.$150M · 2022-02-03
Moore Strategic Ventures
Prime Medicine, Inc.$200M · 2021-07-13
MRL Ventures
Eyebiotech Limited$65M · 2022-02-22
Mubadala Capital
DewPoint Therapeutics, Inc.$150M · 2022-02-03
NS Investment
DewPoint Therapeutics, Inc.$150M · 2022-02-03
PEAK6 Strategic Capital
ImmunOS$74M · 2022-06-08
Polaris Partners
DewPoint Therapeutics, Inc.$150M · 2022-02-03
PSP Investments
Prime Medicine, Inc.$200M · 2021-07-13
Redmile Group
Prime Medicine, Inc.$200M · 2021-07-13
Regeneron Ventures
Enlaza Therapeutics$100M · 2024-04-30
Sanofi Ventures
Abcuro$200M · Unknown date
SV Health Investors
Eyebiotech Limited$65M · 2022-02-22
T. Rowe Price Associates
Prime Medicine, Inc.$200M · 2021-07-13
The Invus Group, LLC
Abata Therapeutics$95M · 2021
Third Rock Ventures
Abata Therapeutics$95M · 2021